Total Payments
$8,186
2024 Payments
$3,540
Companies
12
Transactions
23
Medicare Patients
138
Medicare Billing
$29,589
Payment Breakdown by Category
Consulting$7,640 (93.3%)
Food & Beverage$289.48 (3.5%)
Travel$256.23 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,640 | 4 | 93.3% |
| Food and Beverage | $289.48 | 18 | 3.5% |
| Travel and Lodging | $256.23 | 1 | 3.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,815 | 2 | $0 (2024) |
| Seattle Genetics, Inc. | $1,590 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $525.00 | 1 | $0 (2024) |
| Amgen Inc. | $67.13 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $59.68 | 4 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $42.76 | 3 | $0 (2018) |
| Lilly USA, LLC | $19.43 | 1 | $0 (2017) |
| Ipsen Biopharmaceuticals, Inc | $17.18 | 1 | $0 (2017) |
| AbbVie, Inc. | $13.03 | 1 | $0 (2019) |
| Celgene Corporation | $12.89 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,540 | 2 | AstraZeneca Pharmaceuticals LP ($3,015) |
| 2019 | $2,837 | 4 | AstraZeneca Pharmaceuticals LP ($2,800) |
| 2018 | $1,741 | 13 | Seattle Genetics, Inc. ($1,590) |
| 2017 | $67.34 | 4 | Amgen Inc. ($30.73) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,015.00 | General |
| 11/02/2024 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 03/13/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: Oncology | ||||||
| 03/07/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: Hematology / Oncology | ||||||
| 01/29/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: Virology | ||||||
| 11/28/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2018 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: HEMATOLOGY | ||||||
| 06/12/2018 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2018 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Hematology | ||||||
| 05/15/2018 | Amgen Inc. | Neulasta (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: Oncology | ||||||
| 05/09/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: HEMATOLOGY | ||||||
| 03/28/2018 | Seattle Genetics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 03/21/2018 | Merck Sharp & Dohme Corporation | EMEND (Drug), KEYTRUDA, LYNPARZA | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $256.23 | General |
| Category: Oncology | ||||||
| 02/23/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $33.83 | General |
| Category: Oncology | ||||||
| 01/23/2018 | Lexicon Pharmaceuticals, Inc. | Xermelo (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: Carcinoid Syndrome Diarrhea | ||||||
| 11/30/2017 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $17.18 | General |
| 11/22/2017 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: Oncology | ||||||
| 10/25/2017 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 10/19/2017 | Lilly USA, LLC | CYRAMZA (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 43 | 110 | $33,296 | $9,392 |
| 2021 | 3 | 62 | 130 | $51,330 | $12,943 |
| 2020 | 2 | 33 | 69 | $26,133 | $7,253 |
Total Patients
138
Total Services
309
Medicare Billing
$29,589
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 94 | $28,253 | $8,006 | 28.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 16 | $5,043 | $1,386 | 27.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 84 | $28,812 | $7,315 | 25.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 20 | $13,340 | $3,304 | 24.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 21 | 26 | $9,178 | $2,324 | 25.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 58 | $19,078 | $5,314 | 27.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $7,055 | $1,939 | 27.5% |
About Dr. Gauri Bhide, MD
Dr. Gauri Bhide, MD is a Hematology & Oncology healthcare provider based in Stoneham, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154420719.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gauri Bhide, MD has received a total of $8,186 in payments from pharmaceutical and medical device companies, with $3,540 received in 2024. These payments were reported across 23 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($7,640).
As a Medicare-enrolled provider, Bhide has provided services to 138 Medicare beneficiaries, totaling 309 services with total Medicare billing of $29,589. Data is available for 3 years (2020–2022), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Stoneham, MA
- Active Since 09/21/2006
- Last Updated 04/04/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1154420719
Products in Payments
- LYNPARZA (Drug) $2,800
- ENHERTU (Drug) $525.00
- ADCETRIS (Biological) $290.06
- Neulasta (Biological) $47.38
- JADENU (Drug) $30.84
- AFINITOR (Drug) $28.84
- KEYTRUDA (Biological) $25.60
- Nplate (Biological) $19.75
- CYRAMZA (Drug) $19.43
- EMEND (Drug) $17.16
- Venclexta (Drug) $13.03
- Revlimid (Drug) $12.89
- Xermelo (Drug) $12.26
- Nerlynx (Drug) $11.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.